Stocks
Recursion Pharmaceuticals
AI-powered drug discovery platform.
RXRX key data
Latest reported results
Q2 FY2026 · period ended · filed
Revenue & earnings trend
Last 8 reported quarters, oldest to most recent. Bar height is revenue; the figure below each bar is net income (red = net loss).
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals websiteRXRX price chart
Daily open, high, low and close with volume.
Quotes are delayed at least 15 minutes.
RXRX technical indicators
Computed daily from RXRX's own price history — not third-party ratings. Technical analysis describes past price behaviour; it is information, not investment advice.
Fibonacci retracement
Based on RXRX's high/low over the same history as the chart above.
RXRX frequently asked questions
What is the RXRX stock price today?
Recursion Pharmaceuticals (RXRX) last closed at $3.89 on September 24, 2026. Quotes are delayed at least 15 minutes.
What is the 52-week range for RXRX?
Over the past 52 weeks RXRX has traded between $2.77 and $7.18.
What is Recursion Pharmaceuticals's market cap?
Recursion Pharmaceuticals has a market capitalisation of about $1.98 billion.
Which exchange is RXRX listed on?
RXRX trades on NASDAQ, in the Biological Products, (No Diagnostic Substances) industry.
What was Recursion Pharmaceuticals's most recent revenue?
Recursion Pharmaceuticals reported revenue of $7.67 million for Q2 FY2026, with a net loss of $131.01 million.
What is Recursion Pharmaceuticals's return on equity?
Recursion Pharmaceuticals generated a trailing twelve-month return on equity of about -56.7%.
Is RXRX overbought or oversold?
RXRX's 14-day relative strength index (RSI) is 59.4, which is neutral on the standard 30/70 scale. RSI measures the speed of recent price moves, not a price target — this is not investment advice.
Is RXRX in an uptrend or downtrend?
RXRX's 50-day moving average is currently below its 200-day moving average — a Death Cross (bearish long-term trend) in classic technical-analysis terms. Moving-average crossovers describe past price behaviour, not a forecast.